Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in COPD with Type 2 Inflammation
NCT06959095Phase 3Recruiting
- Sponsor
- GSK
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Depemokimab with Placebo (2 arms). Primary endpoint: Annualized Rate of Moderate/Severe Exacerbations at 104 weeks. Started Jun 2025; status: recruiting.
02
Drugs
depemokimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06959095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959095.